logging in or signing up Neil Avent FunnyGuy Download Post to : URL : Related Presentations : Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Uploaded from authorPOINTLite Insert YouTube videos in PowerPont slides with aS Desktop Copy embed code: (To copy code, click on the text box) Embed: URL: Thumbnail: WordPress Embed Customize Embed The presentation is successfully added In Your Favorites. Views: 277 Category: Education License: All Rights Reserved Like it (0) Dislike it (0) Added: March 20, 2008 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript Slide1: Experiences of EC FPV and FPVI programmes Co-ordination (Bloodgen, 2003-2006) Chair Steering committee (SAFE NoE, 2004-2009) FP7 Roadshow, October 17 2007 Neil Avent Slide2: Lund, Sweden Ulm, Germany Bristol, UK (UWE and BITS) Rotterdam, Netherlands Amsterdam, Netherlands Prague, Czech Republic Barcelona Spain EU BloodGen Consortium Derio, Spain Funding Euro 2.35million UWE - £221,450Slide3: Mixing washed red blood cells with blood group specific antibodies (monoclonal or polyclonal) Some specificities not available or limited Test over 100 years old (Karl Landsteiner 1901, Nobel Laureate) Throughout the EU, routine blood group serology is focussed to the detection of the major clinically significant blood groups ABO, RH, KEL, FY, JK and MNS Alloimmunisation detected by cross match patient serum/donor cells Conventional Blood GroupingSlide4: BLOODchipTM CE-marked Diagnostic kit for defining Blood group genotype 116 different alleles Manufactured by Progenika Biopharma www.progenika.com To be released 4th quarter 2007 Slide5: The Special Non-Invasive Advances in Fetal and Neonatal Evaluation (SAFE) Network of Excellence (NoE) Strong groups in Europe working on Non-invasive prenatal diagnosis (NIPD) – but fragmented, much duplication of effort and no standardisation. Five year research programme funded via the EC Network of Excellence instrument (2004-2009) 50 partners in the EU, India and China International advisory board from EU, USA and Hong Kong www.safenoe.org/ Neil Avent, Chair Network Steering Committee Neil.avent@uwe.ac.uk Funding Euro 12 million UWE - £535, 983Slide6: Amniocentesis 15 – 20 wks 10 – 11 wks 1% RISK SPONTANEOUS MISCARRIAGE Aneuploidy Cystic Fibrosis Myotonic Dystrophy Turner Syndrome Tay-Sachs Disease Huntington’s Disease Sickle Cell Disease Beta-Thalassaemia Chorionic Villus Sampling Invasive Prenatal diagnosis (Current)Slide7: Free Fetal DNA in Maternal plasma (Workpackage 3A) Free Fetal RNA (Workpackage 3B) Fetal cells in the Maternal circulation (Workpackage 1) Automated recognition Of Fetal cells (Workpackage 2) Fetal Proteins in Maternal plasma (Workpackage 3B)Slide8: Experiences of EC FPV and FPVI programmes Advantages of managing these projects Extensive experience of EC project management Superb Networking opportunity Opportunities for funding excellent (3/5 success rate for applications I was involved with) Opportunities for spin-out development significantly enhancedSlide9: Experiences of EC FPV and FPVI programmes Disadvantages of managing these projects UWE budget used to prepare Bloodgen proposal Heavy bureaucracy, especially reporting- be more succinct with deliverables FP7 Now 80% FEC, FP5 & FP6 only 20% Conflict management especially budget and IP issues Extensive travel as co-ordinator Large projects (50+ partners) much more difficult to manage You do not have the permission to view this presentation. In order to view it, please contact the author of the presentation.
Neil Avent FunnyGuy Download Post to : URL : Related Presentations : Share Add to Flag Embed Email Send to Blogs and Networks Add to Channel Uploaded from authorPOINTLite Insert YouTube videos in PowerPont slides with aS Desktop Copy embed code: (To copy code, click on the text box) Embed: URL: Thumbnail: WordPress Embed Customize Embed The presentation is successfully added In Your Favorites. Views: 277 Category: Education License: All Rights Reserved Like it (0) Dislike it (0) Added: March 20, 2008 This Presentation is Public Favorites: 0 Presentation Description No description available. Comments Posting comment... Premium member Presentation Transcript Slide1: Experiences of EC FPV and FPVI programmes Co-ordination (Bloodgen, 2003-2006) Chair Steering committee (SAFE NoE, 2004-2009) FP7 Roadshow, October 17 2007 Neil Avent Slide2: Lund, Sweden Ulm, Germany Bristol, UK (UWE and BITS) Rotterdam, Netherlands Amsterdam, Netherlands Prague, Czech Republic Barcelona Spain EU BloodGen Consortium Derio, Spain Funding Euro 2.35million UWE - £221,450Slide3: Mixing washed red blood cells with blood group specific antibodies (monoclonal or polyclonal) Some specificities not available or limited Test over 100 years old (Karl Landsteiner 1901, Nobel Laureate) Throughout the EU, routine blood group serology is focussed to the detection of the major clinically significant blood groups ABO, RH, KEL, FY, JK and MNS Alloimmunisation detected by cross match patient serum/donor cells Conventional Blood GroupingSlide4: BLOODchipTM CE-marked Diagnostic kit for defining Blood group genotype 116 different alleles Manufactured by Progenika Biopharma www.progenika.com To be released 4th quarter 2007 Slide5: The Special Non-Invasive Advances in Fetal and Neonatal Evaluation (SAFE) Network of Excellence (NoE) Strong groups in Europe working on Non-invasive prenatal diagnosis (NIPD) – but fragmented, much duplication of effort and no standardisation. Five year research programme funded via the EC Network of Excellence instrument (2004-2009) 50 partners in the EU, India and China International advisory board from EU, USA and Hong Kong www.safenoe.org/ Neil Avent, Chair Network Steering Committee Neil.avent@uwe.ac.uk Funding Euro 12 million UWE - £535, 983Slide6: Amniocentesis 15 – 20 wks 10 – 11 wks 1% RISK SPONTANEOUS MISCARRIAGE Aneuploidy Cystic Fibrosis Myotonic Dystrophy Turner Syndrome Tay-Sachs Disease Huntington’s Disease Sickle Cell Disease Beta-Thalassaemia Chorionic Villus Sampling Invasive Prenatal diagnosis (Current)Slide7: Free Fetal DNA in Maternal plasma (Workpackage 3A) Free Fetal RNA (Workpackage 3B) Fetal cells in the Maternal circulation (Workpackage 1) Automated recognition Of Fetal cells (Workpackage 2) Fetal Proteins in Maternal plasma (Workpackage 3B)Slide8: Experiences of EC FPV and FPVI programmes Advantages of managing these projects Extensive experience of EC project management Superb Networking opportunity Opportunities for funding excellent (3/5 success rate for applications I was involved with) Opportunities for spin-out development significantly enhancedSlide9: Experiences of EC FPV and FPVI programmes Disadvantages of managing these projects UWE budget used to prepare Bloodgen proposal Heavy bureaucracy, especially reporting- be more succinct with deliverables FP7 Now 80% FEC, FP5 & FP6 only 20% Conflict management especially budget and IP issues Extensive travel as co-ordinator Large projects (50+ partners) much more difficult to manage